Literature DB >> 4064395

Long-term review of ring total hip arthroplasty.

T A Andrew, D Berridge, A Thomas, R N Duke.   

Abstract

In a five- to 12-year follow-up survey of 179 sequential cementless Ring metal-on-metal total hip arthroplasties, 55 (31%) of the patients were found to have died as a result of nonorthopedic conditions. Analysis of the records demonstrated that 20% of these patients had had poor results attributable to pain. Of the remaining 124 patients, 116 (94%) attended for full clinical and radiologic review yielding a total of 154 hips. Using Ring's classification, 75 hips were judged to have excellent or good results. Forty-one hips were graded as fair or poor as a result of pain, and an additional 15 hips were revised for symptomatic loosening. There were five cases of Brooker Grade IV periarticular ossification, four cases of gross metal reaction requiring prosthetic removal, and two cases of infection. There was considerable variation in the radiographic appearance of the hips, and at times radiographic changes were inconsistent with clinical symptoms. Eleven of the revised hips were converted to longer and larger-diameter uncemented Ring femoral components. Nine of these yielded only fair or poor results at the time of review, whereas both cases in which the femoral component was cemented were associated with good results.

Entities:  

Mesh:

Year:  1985        PMID: 4064395

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  2 in total

1.  Long-term wear of dual mobility total hip replacement cups: explant study.

Authors:  Bertrand Boyer; Thomas Neri; Jean Geringer; Alexandre Di Iorio; Remi Philippot; Frederic Farizon
Journal:  Int Orthop       Date:  2017-06-03       Impact factor: 3.075

2.  Uncemented total hip replacements and thigh pain.

Authors:  G Petrou; M Gavras; A Diamantopoulos; T Kapetsis; N Kremmydas; A Kouzoupis
Journal:  Arch Orthop Trauma Surg       Date:  1994       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.